A detailed history of Nisa Investment Advisors, LLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Nisa Investment Advisors, LLC holds 3,622 shares of MRSN stock, worth $1,955. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,622
Previous 3,131 15.68%
Holding current value
$1,955
Previous $5,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

16 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Jan 17, 2025

BUY
$1.42 - $2.68 $697 - $1,315
491 Added 15.68%
3,622 $5,000
Q3 2024

Oct 24, 2024

SELL
$1.23 - $2.25 $18,042 - $33,005
-14,669 Reduced 82.41%
3,131 $5,000
Q2 2024

Jul 19, 2024

BUY
$2.0 - $4.45 $128 - $284
64 Added 0.36%
17,800 $35,000
Q1 2024

May 01, 2024

BUY
$2.16 - $5.94 $200 - $552
93 Added 0.53%
17,736 $79,000
Q4 2023

Jan 25, 2024

BUY
$1.11 - $2.34 $16,206 - $34,164
14,600 Added 479.79%
17,643 $40,000
Q3 2023

Nov 02, 2023

BUY
$1.06 - $3.91 $234 - $864
221 Added 7.83%
3,043 $3,000
Q2 2023

Aug 11, 2023

BUY
$3.08 - $9.55 $6,812 - $21,124
2,212 Added 362.62%
2,822 $9,000
Q4 2022

Feb 02, 2023

SELL
$5.65 - $7.86 $463 - $644
-82 Reduced 11.85%
610 $4,000
Q3 2022

Nov 07, 2022

BUY
$4.63 - $8.0 $379 - $656
82 Added 13.44%
692 $5,000
Q2 2022

Aug 03, 2022

SELL
$2.84 - $5.0 $136,604 - $240,500
-48,100 Reduced 98.75%
610 $3,000
Q1 2022

Apr 29, 2022

BUY
$3.74 - $6.63 $179,894 - $318,903
48,100 Added 7885.25%
48,710 $194,000
Q3 2021

Oct 18, 2021

SELL
$8.56 - $14.47 $26,108 - $44,133
-3,050 Reduced 83.33%
610 $6,000
Q2 2021

Aug 06, 2021

SELL
$13.28 - $18.07 $77,688 - $105,709
-5,850 Reduced 61.51%
3,660 $50,000
Q1 2021

Apr 26, 2021

SELL
$15.31 - $26.52 $261,801 - $453,492
-17,100 Reduced 64.26%
9,510 $154,000
Q4 2020

Jan 25, 2021

BUY
$16.84 - $27.59 $325,012 - $532,487
19,300 Added 264.02%
26,610 $708,000
Q2 2020

Jul 27, 2020

BUY
$5.24 - $23.4 $38,304 - $171,054
7,310 New
7,310 $171,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $52.5M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Nisa Investment Advisors, LLC Portfolio

Follow Nisa Investment Advisors, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Nisa Investment Advisors, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nisa Investment Advisors, LLC with notifications on news.